Ben-Yehuda O, Cohen D, Alkan M, Greenbaum A, Jelin N, Steinherz R
Israel Defence Forces Medical Corps, Beer Sheva.
Arch Intern Med. 1990 Jan;150(1):209-12.
The efficacy of oral doxycycline, 100 mg/d for 14 days, in reducing the incidence of shigellosis in newcomers to an area hyperendemic for the disease was examined in a double-blind, placebo-controlled trial. Of 107 entrants, 100 completed the study; 50 received the drug and 50 received a placebo. Diarrheal disease and associated symptoms were monitored for 8 weeks. Starting on the 3rd day of the trial, an outbreak was observed, and Shigella flexneri type 2a was isolated from 6 subjects. Eight of the subjects in the treatment group had diarrhea (16%) compared with 37 in the placebo group (74%), providing a 79% protection rate. There was no significant difference in the occurrence of accompanying symptoms between the subjects suffering from diarrhea in both groups, but the duration of disease was shorter in the treatment group. Serologic study of the outbreak showed no significant difference in antibody response to S flexneri between the treatment (14 of 43) and placebo (18 of 39) groups. Doxycycline prophylaxis apparently is effective and probably does not prevent subclinical infection.
在一项双盲、安慰剂对照试验中，研究了口服强力霉素（100毫克/天，共14天）对疾病高度流行地区新迁入者志贺氏菌病发病率的降低效果。107名参与者中，100人完成了研究；50人接受药物治疗，50人接受安慰剂治疗。对腹泻病及相关症状进行了8周的监测。从试验第3天开始，观察到一次暴发，从6名受试者中分离出2a型弗氏志贺菌。治疗组有8名受试者出现腹泻（16%），而安慰剂组有37名（74%），保护率为79%。两组腹泻受试者伴随症状的发生率无显著差异，但治疗组的病程较短。对此次暴发的血清学研究表明，治疗组（43人中有14人）和安慰剂组（39人中有18人）对弗氏志贺菌的抗体反应无显著差异。强力霉素预防显然有效，可能无法预防亚临床感染。
